TXMD — TherapeuticsMD, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 25743 ·
Last close
$2.11
Market Cap
$24.42M
52W High
$2.40
52W Low
$1.90
ADV30
21,205
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 724,000 | — | -723,000 | 95,000 | 37,581,000 | 8,419,000 | 10,608,000 |
| Dec 2025 | 893,000 | — | -1,496,000 | -619,000 | 37,656,000 | 7,483,000 | 10,780,000 |
| Sep 2025 | 784,000 | — | -830,000 | 152,000 | 38,671,000 | 7,115,000 | 11,227,000 |
| Jun 2025 | 952,000 | — | -695,000 | 551,000 | 38,504,000 | 6,069,000 | 11,212,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,454,000
Investing CF
—
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-952,391,000
Inventory
—
Receivables
$3,525,000
ST Investments
—
EBIT TTM
$-4,214,000
Pretax Income TTM
$-653,000
Interest Exp TTM
$10,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,353,000
EBITDA
$-1,407,000
Free Cash Flow
$1,329,250
Enterprise Value
$20,942,648
Total Cash
$8,419,000
Total Debt
$4,824,000
Shares Out
11,574,362
Trailing EPS
$0.01
Book Value
$2.32
ROE
0.3%
ROA
-3.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,022,000 | -4,214,000 | -569,000 | 37,656,000 | 10,780,000 | — | 2,454,000 |
| Dec 2024 | 1,761,000 | -4,844,000 | -2,181,000 | 38,822,000 | 11,452,000 | — | 1,170,000 |
| Dec 2023 | 1,302,000 | -8,523,000 | -10,278,000 | 43,309,000 | 14,022,000 | — | -23,081,000 |
| Dec 2022 | 69,963,000 | 10,663,000 | 111,997,000 | 90,458,000 | 55,315,000 | — | 9,359,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $2.11 · call volume: 28 · put volume: 51
Expected Move to 2026-06-18:
±$1.14
(54.03%) —
implied range
$0.97 –
$3.25
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGVN | Longeveron Inc. | $24.45M | $0.81 | — |
| MRKR | Marker Therapeutics, Inc. | $24.18M | $1.45 | — |
| CLRB | Cellectar Biosciences, Inc. | $24.77M | $3.10 | — |
| BCTX | BriaCell Therapeutics Corp. | $24.80M | $3.42 | — |
| TRAW | Traws Pharma, Inc. | $23.94M | $1.58 | — |
News headlines (Yahoo Finance, 1h cache)
TherapeuticsMD Announces First Quarter 2026 Financial Results
2026-05-12 20:05 · Yahoo
TherapeuticsMD Announces Full Year 2025 Financial Results
2026-03-30 20:05 · Yahoo
TherapeuticsMD: Q3 Earnings Snapshot
2025-11-12 23:04 · Yahoo
TherapeuticsMD Announces Third Quarter 2025 Financial Results
2025-11-12 21:05 · Yahoo
TherapeuticsMD: Q2 Earnings Snapshot
2025-08-12 20:47 · Yahoo
TherapeuticsMD Announces Second Quarter 2025 Financial Results
2025-08-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.